ArticleBlood advances2025
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Reid Shaw et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it